Patients with this subtype have not benefited from existing HER2-directed therapies [9, 10]; therefore, BC with a HER2-low status is currently treated as HER2- (HER2-low and HER2-zero), with patients stratified by hormone receptor status [4, 8, 11]. This evidence concerns the gene NR4A1 and breast cancer.